Dr Chinmay Munje
- Affiliate (School of Cancer Sciences)
The University of Glasgow uses cookies for analytics. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Clarity helps us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
Gómez-Castañeda, E., Hopcroft, L. E.M. , Rogers, S. , Munje, C., Bittencourt-Silvestre, J., Copland, M. , Vetrie, D. , Holyoake, T. and Jørgensen, H. G. (2022) Tyrosine kinase inhibitor independent gene expression signature in CML offers new targets for LSPC eradication therapy. Cancers, 14(21), 5253. (doi: 10.3390/cancers14215253) (PMID:36358672) (PMCID:PMC9655972)
Lebecque, B. et al. (2022) The spliceosome: a new therapeutic target in chronic myeloid leukaemia. Cancers, 14(19), 4695. (doi: 10.3390/cancers14194695) (PMID:36230624) (PMCID:PMC9563771)
Kinstrie, R. et al. (2020) CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. Leukemia, 34(6), pp. 1613-1625. (doi: 10.1038/s41375-019-0684-5) (PMID:31896780) (PMCID:PMC7272220)
Munje, C. and Copland, M. (2018) Exploring stem cell heterogeneity in chronic myeloid leukemia. Trends in Cancer, 4(3), pp. 167-169. (doi: 10.1016/j.trecan.2017.12.001) (PMID:29506666)
Hole, P. S. et al. (2013) Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling. Blood, 122(19), pp. 3322-3330. (doi: 10.1182/blood-2013-04-491944) (PMID:24089327)
Gómez-Castañeda, E., Hopcroft, L. E.M. , Rogers, S. , Munje, C., Bittencourt-Silvestre, J., Copland, M. , Vetrie, D. , Holyoake, T. and Jørgensen, H. G. (2022) Tyrosine kinase inhibitor independent gene expression signature in CML offers new targets for LSPC eradication therapy. Cancers, 14(21), 5253. (doi: 10.3390/cancers14215253) (PMID:36358672) (PMCID:PMC9655972)
Lebecque, B. et al. (2022) The spliceosome: a new therapeutic target in chronic myeloid leukaemia. Cancers, 14(19), 4695. (doi: 10.3390/cancers14194695) (PMID:36230624) (PMCID:PMC9563771)
Kinstrie, R. et al. (2020) CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. Leukemia, 34(6), pp. 1613-1625. (doi: 10.1038/s41375-019-0684-5) (PMID:31896780) (PMCID:PMC7272220)
Munje, C. and Copland, M. (2018) Exploring stem cell heterogeneity in chronic myeloid leukemia. Trends in Cancer, 4(3), pp. 167-169. (doi: 10.1016/j.trecan.2017.12.001) (PMID:29506666)
Hole, P. S. et al. (2013) Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling. Blood, 122(19), pp. 3322-3330. (doi: 10.1182/blood-2013-04-491944) (PMID:24089327)